News
EIGR
--
0.00%
--
Eiger Bio's Avexitide Shows Reduced Rates Of Hypoglycemia, Rescue In Outpatient Setting
Benzinga · 02/23 16:07
Eiger Highlights Publication Of Phase 2 PREVENT Study Results Of Avexitide In Post-Bariatric Hypoglycemia In Journal Of Clinical Endocrinology & Metabolism
PALO ALTO, Calif., Feb. 23, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational
Benzinga · 02/23 13:07
This biopharma is working on COVID-19, but Baird sees 315% upside from different disease opportunity
Baird is sticking with its Outperform rating and a Street-high price target for Eiger BioPharmaceuticals (EIGR) following some new results from a Phase 2 study of its COVID-19 treatment. Full
Seekingalpha · 02/10 00:30
Eiger Highlights Publication Of ILIAD Study Results Of Peginterferon Lambda In COVID-19 Published In Lancet Respiratory Medicine 2021
PALO ALTO, Calif., Feb. 8, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational
Benzinga · 02/08 13:02
BRIEF-Eiger Biopharmaceuticals Announces U.S. Commercial Availability Of Zokinvy
reuters.com · 01/25 13:20
Eiger BioPharmaceuticals Announces US Commercial Availability Of Zokinvy For Progeria And Processing-Deficient Progeroid Laminopathies
PALO ALTO, Calif., Jan. 25, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational
Benzinga · 01/25 13:03
Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy™ (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies
, /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced the commercia...
PR Newswire - PRF · 01/25 13:01
Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies
Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced the commercial launch and availa...
PR Newswire · 01/25 13:00
Global Hypertensive Heart Disease Market 2021 – Industry Analysis, Size, Share, Strategies and Forecast to 2027
Jan 21, 2021 (Heraldkeepers) -- Global Hypertensive Heart Disease Industry Hypertensive heart diseases refer to heart failure, CAD (coronary artery disease),...
Heraldkeepers · 01/21 12:22
Wedbush Reiterates a Buy Rating on Eiger Biopharmaceuticals (EIGR)
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Eiger Biopharmaceuticals (EIGR), with a price target of $22.00. The
SmarterAnalyst · 01/19 11:45
Ameriprise Financial Reports In 13G Filing A Passive Stake Of 12.06% In Eiger BioPharmaceuticals
-SEC Filing
SEC Filing · 01/11 16:55
Eiger targets Zokinvy EMA approval and late-stage trial initiation for Lambda in 2021
Eiger BioPharmaceuticals ([[EIGR]] -5.6%) expects EMA approval for its Hutchinson-Gilford progeria syndrome treatment Zokinvy, and plans to start its Phase 3 HDV LIMT-2 ((Lambda)) trial, both in the second half of
Seekingalpha · 01/07 17:00
Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans
, /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today updated on progress acr...
PR Newswire - PRF · 01/07 13:00
Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans
, /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today updated on progress acr...
PR Newswire - PRF · 01/07 13:00
Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans
, /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today updated on progress acr...
PR Newswire - PRF · 01/07 13:00
Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans
PR Newswire · 01/07 13:00
Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans
Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today updated on progress across its product pip...
PR Newswire · 01/07 13:00
A New Gene-Editing Technique May Be Able to Help Children Who Prematurely Age
Barrons.com · 01/06 16:00
A New Gene-Editing Technique May Be Able to Help Children Who Prematurely Age
Scientists report that a novel gene-editing technology was able to correct the genetic mutation that causes progeria in lab mice and spare them its effects.
Barrons.com · 01/06 16:00
A New Gene-Editing Technique May Be Able to Help Children Who Prematurely Age
Barrons.com · 01/06 16:00
Webull provides a variety of real-time EIGR stock news. You can receive the latest news about Eiger through multiple platforms. This information may help you make smarter investment decisions.
About EIGR
Eiger BioPharmaceuticals Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing drugs for serious diseases. Its product candidate pipeline includes programs, including Lonafarnib (LNF), Peginterferon Lambda (lambda), LNF in Progeria and Progeroid Laminopathies (PL), Avexitide. LNF is an orally bioavailable, farnesylation inhibitor in Phase-III clinical trials for Hepatitis Delta Virus (HDV) infection. Lambda is a late-stage, type III interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. It is also developing lonafarnib for treatment of Progeria and Progeroid Laminopathies. Avexitide is a peptide that it is being developed as a treatment for Post-Bariatric Hypoglycemia (PBH). Avexitide is also being developed for Congenital Hyperinsulinism (CHI).